期刊文献+

二甲双胍的多重抗癌机制 被引量:7

原文传递
导出
摘要 二甲双胍是临床上最常用的抗高血糖药物之一,被普遍认为是一个安全廉价的药物,是美国糖尿病学会(ADA)和欧洲糖尿病协会(EASD)所共识的,及中国糖尿病防治指南(2010版)推荐的2型糖尿病一线治疗和糖尿病前期预防药物。
作者 张丹丹 刘芳
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第12期956-958,共3页 National Medical Journal of China
基金 国家自然科学基金(81070650、81270397)
  • 相关文献

参考文献38

  • 1Cohen P. Metformin for the induced metabolic syndrome, prevention of androgen deprivation obesity and type 2 diabetes. MedI-Iypothese, 2009, 72 : 227-228.
  • 23enlor IA. l'ype 2 Olabetes, metlormln an lactic acloosls- defining the risk and promoting safe practice. Diabet Med, 2012, 29 : 161-163.
  • 3Huxley R, Barzi F, Woodward M, et al. Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer, 2005, 92 : 2076-2083.
  • 4Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: meta-analysis. J Natl Cancer Inst, 2005, 97: 1679-1686.
  • 5Larsson SC, Orsini N, Wolk A, et al. Diabetes mellitus and risk of bladder cancer: meta-analysis. Diabetologia, 2006, 49: 2819- 2823.
  • 6EI-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol, 2006, 4: 369-380.
  • 7Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prey, 2006, 15: 2056-2062.
  • 8Larsson SC, Mantzoros CS, Wolk S. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer, 2007, 121: 856- 862.
  • 9Friberg E, Orsini N, Wolk A, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia, 2007, 50: 1365-1374.
  • 10Mitri J, Castillio J, Pittas AG. Diabetes and risk of non-Hodgki's lymphoma: a meta-analysis of observational studies. Diabetes Care, 2008, 31: 2391-2397.

同被引文献77

  • 1张幼怡.二甲双胍的心脏保护作用机制研究进展[J].中国医学前沿杂志(电子版),2011,3(5):21-23. 被引量:8
  • 2印剑,王长松,王仰坤,等.双侧肺腺癌合并胃原发性腺癌1例[J].胃肠道学和肝病学杂志,2010;19(10):921-2.
  • 3伍华,陈敏,邵丽香,等.西格列汀联合二甲双胍治疗初发2型糖尿病的临床观察[J].中国医药,2013,8(z1):18-19.
  • 4Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, et al. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial[J]. Cardiovasc Diabetol, 2012, 11: 64.
  • 5Nadeau DA. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach[J]. Postgrad Med, 2013, 125(3): 112-126.
  • 6Kato Y, Koide N, Komatsu T, et al. Metformin attenuates production of nitric oxide in response to lipopolysaccharide by inhibiting MyD88-independent pathway[J]. Honn Metab Res, 2010, 42(9): 632-636.
  • 7Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus[J]. CMAJ, 2005, 172(2): 213-226.
  • 8Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus[J]. Drugs, 1995, 49(5): 721-749.
  • 9A1-Khalili L, Forsgren M, Kannisto K, et al. Enhanced insulin- stimulated glycogen synthesis in response to insulin, metformin or.rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co- activator l[J]. Diabetologia, 2005, 48(6): 1173-1179.
  • 10Thakkar B, Aronis KN, Vamvini MT, et al. Metformin and sulfonylureas in relation to cancer risk in type lI diabetes patients: a meta-analysis using primary data of published studies [J]. Metabolism, 2013, 62(7): 922-934.

引证文献7

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部